Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSPB1 | P04792 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 2/20 | 0.40 |
| ▸ | CA2 | P00918 | 2/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.40 |
| ▸ | CES2 | O00748 | 1/20 | 0.40 |
| ▸ | CES1 | P23141 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | LTA4H | P09960 | 1/20 | 0.38 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.38 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20787653 | 0.79 | STS (0.30) | — | |
| SCHEMBL21489392 | 0.78 | HSPB1 (0.36) | HSPB1CA1CA2CA9CES2 | |
| SCHEMBL3453447 | 0.75 | RECQL (0.42) | LTA4HMEN1POLBKMT2AMAPK1 | |
| SCHEMBL17724920 | 0.75 | CRYZ (0.36) | CES2CES1ALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL3197086 | 0.75 | CRYZ (0.36) | CES2CES1ALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL17447006 | 0.75 | CRYZ (0.36) | CES2CES1ALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL5769257 | 0.75 | L3MBTL1 (0.39) | CES2CES1ALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL3187832 | 0.75 | CRYZ (0.36) | CES2CES1ALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL3187838 | 0.75 | CRYZ (0.36) | CES2CES1ALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL15112222 | 0.75 | CRYZ (0.36) | CES2CES1ALDH1A1LMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107148423-B | Thionucleoside derivative or salt thereof and pharmaceutical composition | 富士胶片株式会社 | 2021-07-30 | — | — | CN | disclosed |
| EP-3730509-A1 | COMPOUND FOR TREATING METABOLIC DISEASES AND PREPARATION METHOD AND USE THEREOF | Xi' An Biocare Pharma (CN) | 2020-10-28 | — | — | EP | disclosed |
| EP-3214090-B1 | THIONUCLEOSIDE DERIVATIVE OR SALT THEREOF, AND PHARMACEUTICAL COMPOSITION | FUJIFILM CORP (JP) | 2020-08-19 | — | — | EP | disclosed |
| US-10385089-B2 | Thionucleoside derivative or salt thereof, and pharmaceutical composition | FUJIFILM CORPORATION (JP) | 2019-08-20 | — | — | US | disclosed |
| US-10385089-B2 | Thionucleoside derivative or salt thereof, and pharmaceutical composition | FUJIFILM CORPORATION (JP) | 2019-08-20 | — | — | US | disclosed |
| US-20180319834-A1 | THIONUCLEOSIDE DERIVATIVE OR SALT THEREOF, AND PHARMACEUTICAL COMPOSITION | FUJIFILM CORPORATION (JP) | 2018-11-08 | — | — | US | disclosed |
| US-10059734-B2 | Thionucleoside derivative or salt thereof, and pharmaceutical composition | FUJIFILM CORPORATION (JP) | 2018-08-28 | — | — | US | disclosed |
| CN-108137639-A | Nicotinamide mononucleotide derivative and application thereof | 麦德龙国际生物科技有限责任公司 | 2018-06-08 | — | — | CN | disclosed |
| EP-3214090-A1 | THIONUCLEOSIDE DERIVATIVE OR SALT THEREOF, AND PHARMACEUTICAL COMPOSITION | Fujifilm Corporation (JP) | 2017-09-06 | — | — | EP | disclosed |
| US-20170233429-A1 | THIONUCLEOSIDE DERIVATIVE OR SALT THEREOF, AND PHARMACEUTICAL COMPOSITION | FUJIFILM CORPORATION (JP) | 2017-08-17 | — | — | US | disclosed |
| US-20170233429-A1 | THIONUCLEOSIDE DERIVATIVE OR SALT THEREOF, AND PHARMACEUTICAL COMPOSITION | FUJIFILM CORPORATION (JP) | 2017-08-17 | — | — | US | disclosed |
| US-20170233429-A1 | THIONUCLEOSIDE DERIVATIVE OR SALT THEREOF, AND PHARMACEUTICAL COMPOSITION | FUJIFILM CORPORATION (JP) | 2017-08-17 | — | — | US | disclosed |
| WO-2016068341-A1 | THIONUCLEOSIDE DERIVATIVE OR SALT THEREOF, AND PHARMACEUTICAL COMPOSITION | 富士フイルム株式会社 | 2016-05-06 | — | — | WO | disclosed |
| CN-101747404-B | Glycyrrhetinic acid cyclic phosphonate ester derivative and preparation method thereof | OCEAN UNIV CHINA | 2012-06-27 | — | — | CN | disclosed |
| CN-101747404-A | Glycyrrhetinic acid cyclic phosphonate ester derivative and preparation method thereof | OCEAN UNIV CHINA | 2010-06-23 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180319834-A1 | THIONUCLEOSIDE DERIVATIVE OR SALT THEREOF, AND PHARMACEUTICAL COMPOSITION | SLC11A2, RNASE1, KRAS | HSPB1 2936/4885CA1 2690/4885CA2 2431/4885 |
| US-10385089-B2 | Thionucleoside derivative or salt thereof, and pharmaceutical composition | SLC11A2, RNASE1, KRAS | HSPB1 2936/4885CA1 2690/4885CA2 2431/4885 |
| US-10059734-B2 | Thionucleoside derivative or salt thereof, and pharmaceutical composition | SLC11A2, RNASE1, TYMP | HSPB1 2233/4885CA1 2627/4885CA2 2614/4885 |
| US-20170233429-A1 | THIONUCLEOSIDE DERIVATIVE OR SALT THEREOF, AND PHARMACEUTICAL COMPOSITION | SLC11A2, RNASE1, TYMP | HSPB1 2233/4885CA1 2627/4885CA2 2614/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.